Prudential Financial Inc. Sells 25,273 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Prudential Financial Inc. decreased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 20.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 96,817 shares of the company's stock after selling 25,273 shares during the period. Prudential Financial Inc. owned approximately 0.15% of Kymera Therapeutics worth $3,895,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. grew its position in Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after purchasing an additional 95,547 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in Kymera Therapeutics during the third quarter worth about $1,315,000. Bamco Inc. NY acquired a new stake in Kymera Therapeutics during the third quarter worth about $1,183,000. Cinctive Capital Management LP bought a new position in Kymera Therapeutics during the third quarter valued at about $2,688,000. Finally, HighTower Advisors LLC acquired a new position in Kymera Therapeutics in the 3rd quarter valued at approximately $494,000.

Insider Activity at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock valued at $455,202 over the last quarter. Corporate insiders own 15.82% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several analysts have recently weighed in on KYMR shares. Stephens reissued an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Leerink Partners reissued an "outperform" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th. BTIG Research assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a "buy" rating and a $60.00 price objective for the company. Citigroup assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price on the stock. Finally, HC Wainwright increased their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Kymera Therapeutics Stock Down 10.1 %

KYMR traded down $2.67 during trading on Thursday, hitting $23.69. The company's stock had a trading volume of 709,266 shares, compared to its average volume of 528,857. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -10.12 and a beta of 2.22. The firm's 50 day moving average price is $34.88 and its two-hundred day moving average price is $41.37. Kymera Therapeutics, Inc. has a 12 month low of $23.65 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.